Abstract Body

Background: Access to combination antiretroviral therapy (ART) in sub-Saharan Africa (SSA) has expanded due to a large number of national initiatives. Previous studies have shown higher rates of NRTI and NNRTI-related toxicity when comparing patients on ART in SSA with those in resource-replete settings. The Tshepo study is the first to extensively evaluate the association of host genetic factors on ART-related toxicity heterogeneity in SSA. Methodology: The Tshepo study is a 3-year randomized clinical study following 650 ART-naive adults (69.4% female) from Botswana who initiated first-line NNRTI-based ART. We conducted a large-scale gene-centric association study on Tshepo participants with sufficient DNA using the Illumina Human CardioMetabolo Beadchips enriched in markers for metabolic and cardiovascular genes (198K), including mitochondrial, ADME, renal, and immune response genes. After quality control, 133,822 SNPs were tested for association with 5 NRTI/NNRTI-associated toxicities in 568 individuals. Of these, 62 had peripheral neuropathy (PN), 20 had NVP-associated hypersensitivity cutaneous reaction (NS), 19 had ZDV-related anemia (ZA), 19 had pancreatitis (PA), and 17 had moderate-severe hyperlactatemia/lactic acidosis (LA). Logistic regressions in an additive model were performed and adjusted for gender, age, CD4, plasma HIV-RNA level, and BMI at baseline, as well as for the first two eigenvectors from the population stratification analysis. Results: Although no SNP reached the Bonferroni study-wide significance level (P<3.7x10-7), several SNPs met the suggestive significance threshold (P<10-5): rs2503875 (chr10, OR=7, P=5x10-7) and rs7767230 (chr6, OR=9, P=2x10-6) for PN; rs702864 (chr21, OR=6, P=7x10-6), rs2902211 and rs11589503 (chr1, OR=5-6, P=9x10-6) for NS; three chr6 markers (OR=9-10, P=4-7x10-6), and two chr18 markers (OR=9-11, P=5-9x10-6) for PA. Conclusions: This first large genetic study to evaluate ART-associated toxicity in Africa revealed putative candidate loci for several potentially lifethreatening and/or debilitating NRTI/NNRTI-related toxicities with robust effect sizes. These preliminary findings warrant validation and further investigation.